Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer

Bußmann, Lara; Busch, Chia‐Jung; Lőrincz, Balázs B.; Rieckmann, Thorsten; Block, Andreas; Knecht, Rainald

doi:10.1007/s00405-015-3893-1

Cited by 10 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, cisplatin resistance and a significant incidence of toxic side effects ( e . g ., ototoxicity and nephrotoxicity) pose serious issues in the management of this disease [ 1 , 2 , 4 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor

et al. 2017

View full text Add to dashboard Cite

Chemoresistant cancer cells express high levels of aldehyde dehydrogenases (ALDHs), particularly in head and neck squamous cell carcinoma (HNSCC). The ALDH family of enzymes detoxify both exogenous and endogenous aldehydes. Since many chemotherapeutic agents, such as cisplatin, result in the generation of cytotoxic aldehydes and oxidative stress, we hypothesized that cells expressing high levels of ALDH may be more chemoresistant due to their increased detoxifying capacity and that inhibitors of ALDHs may sensitize them to these drugs. Here, we show that overall ALDH activity is increased with cisplatin treatment of HNSCC and that ALDH3A1 protein expression is particularly enriched in cells treated with cisplatin. Activation of ALDH3A1 by a small molecule activator (Alda-89) increased survival of HNSCC cells treated with cisplatin. Conversely, treatment with a novel small molecule ALDH inhibitor (Aldi-6) resulted in a marked decrease in cell viability, and the combination of Aldi-6 and cisplatin resulted in a more pronounced reduction of cell viability and a greater reduction in tumor burden in vivo than what was observed with cisplatin alone. These data indicate that ALDH3A1 contributes to cisplatin resistance in HNSCC and that the targeting of ALDH, specifically, ALDH3A1, appears to be a promising strategy in this disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Two‐thirds of HNSCC patients exhibit advanced stage disease at diagnosis, 4 and the prognosis of these patients has not changed over the last decades 5 . Besides surgery, cisplatin (CDDP) combined or not with radiotherapy (RT) has been used in HNSCC patient's treatment 6 ; however, the chemoresistance of HNSCC has been reported 7 …”

Section: Introductionmentioning

confidence: 99%

microRNAs deregulation in head and neck squamous cell carcinoma

et al. 2020

View full text Add to dashboard Cite

Head and neck (HN) squamous cell carcinoma (SCC) is the eighth most common human cancer worldwide. Besides tobacco and alcohol consumption, genetic and epigenetic alterations play an important role in HNSCC occurrence and progression. microRNAs (miRNAs) are small noncoding RNAs that regulate cell cycle, proliferation, development, differentiation, and apoptosis by interfering in gene expression. Expression profiling of miRNAs showed that some miRNAs are upregulated or downregulated in tumor cells when compared with the normal cells. The present review focuses on the role of miRNAs deregulations in HNSCC, enrolled in risk, development, outcome, and therapy sensitivity. Moreover, the influence of single nucleotide variants in miRNAs target sites, miRNAs seed sites, and miRNAs-processing genes in HNSCC was also revised. Due to its potential for cancer diagnosis, progression, and as a therapeutic target, miRNAs may bring new perspectives in HNSCC understanding and therapy, especially for those patients with no or insufficient treatment options.

show abstract

“…Estos crecimientos celulares pueden tener diversas etiologías, pero se les asocia más a factores de riesgo como el uso concomitante de tabaco y alcohol e infecciones como el virus de papiloma humano y Epstein-Barr. Otros factores que también pueden causar esta patología son una mala higiene dental, malos hábitos alimenticios y reflujo gastroesofágico [1][2][3][4][5].…”

Section: Introduccionunclassified

Eficacia de la quimioterapia de inducción en el tratamiento del cáncer de cabeza y cuello en el Hospital San Juan de Dios, del año 2010 al 2013.

Barrantes¹,

Rojas²,

Quesada³

et al. 2018

Rev Med UCR

View full text Add to dashboard Cite

Objetivos: evaluar la efectividad de la quimioterapia de inducción en el tratamiento del cáncer de cabeza y cuello en el Hospital San Juan de Dios, del 2010 al 2013. Métodos: Los expedientes clínicos de los pacientes diagnosticados con cáncer de cabeza y cuello y tratados del año 2010 al 2014, fueron analizados de manera retrospectiva. Se analizó información demográfica, clínica y de tratamiento. Las tasas de supervivencia y sobrevida libre de progresión fueron calculadas por medio de gráficos de Kaplan-Meier. La mediana de seguimiento para los 33 pacientes fue de 20 meses. Del total de los pacientes incluidos en el estudio, 7 pacientes (21%) fueron tratados con quimioterapia de inducción mientras que 26 pacientes (79%) recibieron quimioradioterapia como tratamiento definitivo. Conclusión: La respuesta a los 6 meses refleja una respuesta completa del 79% en ambos grupos, sin embargo, no existe una diferencia estadísticamente significativa en la supervivencia de los pacientes con tratamiento de inducción respecto a aquellos que no recibieron este tratamiento.

show abstract

Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer

Cited by 10 publications

References 33 publications

Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor

Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor

microRNAs deregulation in head and neck squamous cell carcinoma

Eficacia de la quimioterapia de inducción en el tratamiento del cáncer de cabeza y cuello en el Hospital San Juan de Dios, del año 2010 al 2013.

Contact Info

Product

Resources

About